- Hypersensitivity to any of the ingredients of the product
- Second or third degree AV block
- Sinus node dysfunction
Note Except in patients having functioning artificial pacemaker
See Supplemental Patient Information
- Life threatening cardiac arrest, ventricular arrhythmias/MI may be induced by pharmacologic stress agents
- Before administration cardiac resuscitation equipment and trained staff should be available, in serious reactions, use aminophylline, adenosine antagonist
- Regadenoson, an adenosine receptor agonist, may depress SA and AV nodes and cause first-, second-, or third-degree AV block, or sinus bradycardia
- Induces arterial vasodilation and hypotension
- Clinically there may be increases in blood pressure
- Bronchoconstriction and respiratory compromise may occur, so before administration bronchodilator therapy and resuscitative measures should be available
Cautions: Use cautiously in
- Autonomic dysfunction
- Hypovolemia
- Left main coronary artery stenosis
- Stenotic valvular heart disease
- Pericarditis
- Pericardial effusion
- Stenotic carotid artery disease with cerebrovascular insufficiency
- Bronchoconstrictive disease
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Supplemental Patient Information
- Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, and theophylline, for at least 12 hours before a scheduled radionuclide MPI
Pregnancy Category:C
Breastfeeding: Safety unknown. Manufacturer recommends discontinuation of nursing or discontinuation of therapy, by analyzing risk and benefit ratio in nursing mothers. Interrupting nursing for 10 hours after administration would minimize exposure of the breastfed infant.
